Operating Lease, Right-of-Use Asset of ARS Pharmaceuticals, Inc. from 31 Dec 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
ARS Pharmaceuticals, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2020 to 30 Sep 2025.
  • ARS Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $1,439,000, a 1464% increase year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

ARS Pharmaceuticals, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,439,000 +$1,347,000 +1464% 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $1,564,000 +$1,418,000 +971% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $72,000 -$126,000 -64% 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $37,000 -$213,000 -85% 31 Dec 2024 10-Q 10 Nov 2025 2025 Q3
Q3 2024 $92,000 -$208,000 -69% 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $146,000 -$203,000 -58% 30 Jun 2024 10-Q 06 Aug 2024 2024 Q2
Q1 2024 $198,000 -$200,000 -50% 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $250,000 -$195,000 -44% 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $300,000 +$300,000 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $349,000 -$3,568,000 -91% 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $398,000 -$4,086,000 -91% 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $445,000 -$176,000 -28% 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $0 -$5,011,000 -100% 30 Sep 2022 10-Q 02 Nov 2022 2022 Q3
Q2 2022 $3,917,000 +$2,302,000 +143% 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $4,484,000 +$2,584,000 +136% 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $621,000 -$1,559,000 -72% 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $5,011,000 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
Q2 2021 $1,615,000 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q1 2021 $1,900,000 31 Mar 2021 10-Q 13 May 2021 2021 Q1
Q4 2020 $2,180,000 31 Dec 2020 10-K 31 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.